Hill Publishing Group | contact@hillpublisher.com

Hill Publishing Group

Location:Home / Journals / International Journal of Clinical and Experimental Medicine Research /

DOI:http://dx.doi.org/10.26855/ijcemr.2022.07.005

Preliminary Exploration of New Treatment Mode of Traditional Chinese Medicine and Western Medicine Supplement for Tumor Patients

Date: June 16,2022 |Hits: 229 Download PDF How to cite this paper

Chuanhao Jin

First Clinical Medical College, Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, China.

*Corresponding author: Chuanhao Jin

Abstract

Traditional Chinese Medicine (TCM) is commonly employed in Chinese cancer centers, although formal scientific examination of this practice is still in its infancy in the Chinese cancer community. TCM practitioners and cancer patients’ viewpoints and experiences were examined in the first step toward establishing a clinical assessment of TCM for use in treating cancer patients. Inductive theme analysis was performed using text transcripts and field notes. As a result of our research, we discovered that patients’ decisions to employ TCM for cancer treatment are self-help processes rooted in the ancient Chinese concept of life. TCM was seen as a safe and effective treatment by participants. They regarded TCM's ability to personalize therapy to individual patients as a key component of safe and effective care. In addition, participants cited TCM’s long-term benefits, the advantages of group therapy, and its cheap cost as crucial aspects. Clinical research, according to participants, is critical to the acceptance and spread of TCM in the West. We believe that the results of this study will add to our understanding of how TCM is currently being used in China to treat cancer, as well as give information for future clinical studies in the West.

References

[1] Z.-Q. Y. C. L. S.-J. C. Q. S. T.-R. Z. N. S. P. Z.-P. Y. J.-M. Y. Ji-Wei Wang. (2016). “Cancer survivors’ perspectives and ex-perience on western medicine and traditional Chinese medicine treatment and rehabilitation: a qualitative study,” Patient Preference and Adherence, pp. 2-6, 2016. 

[2] M. H. M. Z. S. Z. L. C. H. Z. H. Y. L. Qiang Sun. (2021). “Traditional Chinese Medicine and Colorectal Cancer: Implications for Drug Discovery,” Systematic review, 2021. 

[3] C. T. S. Y. e. a. Lee YW. (2015). “Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study. Cancer,” 120: 1338-1344, 2015. 

[4] A. F. B. G. I. A. P. M. T. A. T. L. V. K. e. a. Almeida. (2018). “Bioavailability of Quercetin in Humans with a Focus on Interindividual Variation. Compr. Rev. Food Sci. Food Saf.,” pp. 17, 714-731, 2018. 

[5] B. N. P. C. L. G. E. M. Smithson J. (2016). “The experience of using complementary therapies after a diagnosis of cancer: a qualitative synthesis. Health (London).,” 16: 19-39, 2016. 

[6] A. P. Madan RA. (2013). “Recent advances revolutionize treatment of metastatic prostate cancer. Future Oncol,” 9: 1133-1144., 2013. 

[7] I. M.-R. A. G. R. R. J. a. R. M. Andújar. (2018). “Shikonin Prevents Early Phase Inflammation Associated with Azoxymethane/Dextran Sulfate Sodium-Induced Colon Cancer and Induces Apoptosis in Human Colon Cancer Cells. Planta Med.,” pp. 674-683, 2018. 

[8] L. D. O. Z. F. L. F. C. J.-F. P. C. e. a. Bu. (2020). “Traditional Chinese Medicine Formulas, Extracts, and Compounds Promote Angiogenesis. Biomed. Pharmacother.,” pp. 132, 110855., 2020. 

[9] E. E. L. M. e. a. McCorkle R. (2013). “Self-management: enabling and empowering patients living with cancer as a chronic illness. CA Cancer J Clin.,” 61: 50-62., 2013. 

[10] S. I. E. M. e. a. Ferlay J. (2017). “Cancer Incidence and Mortality Worldwide: IARC Cancer Base No 11,” International Agency for Research on Cancer, 2017. 

[11] C. S. P. B. A. a. S. M. Buhrmann. (2020). “Resveratrol Suppresses Cross-Talk between Colorectal Cancer Cells and Stromal Cells in Multicellular Tumor Microenvironment: A Bridge between In Vitro and In Vivo Tumor Microenvironment,” 2020. 

[12] W. L. L. J. L. S. W. Q. Wang Y. (2015). “Comparison and analysis of the incidence and mortality rate of cancer in developed and developing countries. Chin J Clin Oncol.,” 39: 679-682., 2015. 

[13] F. A. M. W. M. F. M. P. G. D. Psutka SP. (2014). “Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol.,” 63: 486-492, 2014. 

[14] Y.-T. C. F. Z. C. F. B. T. H.-Y. N. H. e. a. Chan. (2020). “Ancient Chinese Medicine Herbal Formula Huanglian Jiedu Decoction as a Neoadjuvant Treatment of Chemotherapy by Improving Diarrhea and Tumor Response. Front. Pharmacol.,” 2020. 

[15] H.-R. N. Yen. (2021). “Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients,” China Medical University Hospital, 2021. 

[16] L. Z. H. F. J. L. C. L. Z. C. R. e. a. Chu. (2015). “The Traditional Chinese Medicinal Formula BDL301 Suppresses Tumor Growth by Inhibiting STAT3 Pathway and Inducing Apoptosis in Colorectal Cancer Cells. DNA Cel Biol.,” pp. 34, 178-188, 2015. 

[17] S. H. B. A. H.-M. D. Q. X. L. S. K.-P. e. a. Deng. (2014). “Teng-Long-Bu-Zhong-Tang, a Chinese Herbal Formula, Enhances Anticancer Effects of 5 - Fluorouracil in CT26 colon Carcinoma. BMC Complement. Altern. Med.,” pp. 13, 128, 2014. 

[18] J. L. L. L. J. Y. C. Z. H. a. L. L. Dong. (2018). “Philosophical Thinking of Chinese Traditional Medicine. Tradit. Med.,” pp. 1-10, 2018. 

[19] Y. M. Z. Z. L. W. W. G. M. J. X. e. a. Fan. (2020). “Anti-tumor Activities and Mechanisms of Traditional Chinese Medicines Formulas: A Review. Biomed. Pharmacother,” 2020. 

[20] W. A. H. P. C. a. Y. D. Feng. (2019). “Gut Microbiota, a New Frontier to Understand Traditional Chinese Medicines. Pharmacol. Res.,” pp. 142, 176-191, 2019. 

[21] T. W. W. H. L. K. Liu CH1. (2013). “Cancer patients’ experience of combined treatment with conventional and traditional Chinese medicine: a biopsychosocial phenomenon. Cancer Nurs.,” 34(6): 495-502, 2013.

How to cite this paper

Preliminary Exploration of New Treatment Mode of Traditional Chinese Medicine and Western Medicine Supplement for Tumor Patients

How to cite this paper: Chuanhao Jin. (2022) Preliminary Exploration of New Treatment Mode of Traditional Chinese Medicine and Western Medicine Supplement for Tumor PatientsInternational Journal of Clinical and Experimental Medicine Research6(3), 257-263.

DOI: http://dx.doi.org/10.26855/ijcemr.2022.07.005

Volumes & Issues

Free HPG Newsletters

Add your e-mail address to receive free newsletters from Hill Publishing Group.

Contact us

Hill Publishing Group

8825 53rd Ave

Elmhurst, NY 11373, USA

E-mail: contact@hillpublisher.com

Copyright © 2019 Hill Publishing Group Inc. All Rights Reserved.